We are live on ! Find out more
NMTR

9 Meters Biopharma
NMTR

Delisted

NMTR was delisted on the 25th of July, 2023.

Back to rankings

26 hedge funds and large institutions have $16.3M invested in 9 Meters Biopharma in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,830% more capital invested

Capital invested by funds: $844K → $16.3M (+$15.4M)

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

13% more funds holding

Funds holding: 23 → 26 (+3)

Holders
26
Holders Change
+3
Holders Change %
+13.04%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
4
Closed
8
Calls
$62K
Puts
–
Net Calls
+$62K
Net Calls Change
+$14K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$14.5M
2
GPCM
Granite Point Capital Management
Massachusetts
+$613K
3
TRCT
Tower Research Capital (TRC)
New York
+$106K
4
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$45.1K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$29.7K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$54.5K
2
BlackRock
BlackRock
New York
-$46.9K
3
Citadel Advisors
Citadel Advisors
Florida
-$28.8K
4
HWA
Heritage Wealth Advisors
Virginia
-$5.64K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$3.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$14.6M +$14.5M +1,285,838 New
GPCM
2
Granite Point Capital Management
Massachusetts
$623K +$613K +54,351 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$410K -$3.3K -293 -0.8%
BlackRock
4
BlackRock
New York
$156K -$46.9K -4,160 -23%
TRCT
5
Tower Research Capital (TRC)
New York
$108K +$106K +9,431 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$77K +$12.5K +1,109 +19%
Renaissance Technologies
7
Renaissance Technologies
New York
$74K -$54.5K -4,830 -43%
CAPTRUST Financial Advisors
8
CAPTRUST Financial Advisors
North Carolina
$58K +$45.1K +4,000 New
Qube Research & Technologies (QRT)
9
Qube Research & Technologies (QRT)
United Kingdom
$30K +$29.7K +2,636 New
Northern Trust
10
Northern Trust
Illinois
$24K – – –
SXL
11
Summit X LLC
Missouri
$22K +$2.25K +200 +12%
ACP
12
Ashfield Capital Partners
California
$19K – – –
RJFSA
13
Raymond James Financial Services Advisors
Florida
$16K +$7.89K +700 +106%
RE
14
RBC Europe
United Kingdom
$14.3K – – –
Janney Montgomery Scott
15
Janney Montgomery Scott
Pennsylvania
$13K +$13K +1,150 New
HWA
16
Heritage Wealth Advisors
Virginia
$11.5K -$5.64K -500 -33%
Victory Capital Management
17
Victory Capital Management
Texas
$8K +$1.92K +170 +30%
Squarepoint
18
Squarepoint
New York
$8K +$7.93K +703 New
RC
19
RegentAtlantic Capital
New Jersey
$7K +$6.76K +600 New
CWS
20
Cypress Wealth Services
California
$6K +$5.64K +500 New
Wells Fargo
21
Wells Fargo
California
$3K +$2.84K +252 +3,600%
SPIA
22
Steward Partners Investment Advisory
New York
$2K +$2.21K +196 New
CG
23
Cutler Group
California
$1K – – –
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$1K +$68 +6 +4%
Citadel Advisors
25
Citadel Advisors
Florida
– -$28.8K -2,553 Closed
1
2

NMTR Hedge Fund Activity: Q2 2020 in Review

26 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q2 2020, worth a combined $16.3M — up 1,830% from $844K a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new NMTR positions and 8 closed out — a net gain of 3 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $14.5M. The largest seller was Renaissance Technologies, cutting an estimated $54.5K.

  • 26 institutional investors held 9 Meters Biopharma (NMTR) as of Q2 2020, up from 23 in Q1 2020.
  • Funds reported $16.3M of 9 Meters Biopharma stock for Q2 2020, up 1,830% quarter-over-quarter.
  • 11 funds opened new 9 Meters Biopharma positions in Q2 2020 and 8 closed out, a net change of +3 holders.
  • The largest 9 Meters Biopharma buyer in Q2 2020 was OrbiMed, an estimated $14.5M added.
  • The largest 9 Meters Biopharma seller in Q2 2020 was Renaissance Technologies, an estimated $54.5K sold.

Based on aggregated 13F filings for Q2 2020.